Report on sepsis market opportunity & early diagnosis impact Just got caught up on the independent report contracted by ASEP Medical ($ASEP.c) to better define the market opportunity, and estimate the impact of early and accurate sepsis diagnosis.
The conclusion that "substantial savings in lives, hospital days and costs result when a diagnostic assay becomes available to diagnose the onset of severe sepsis enabling early treatment" is quite significant as this could result in an overall savings of up to $22 billion annually in the US alone.
"Overall, early and appropriate antibiotic treatment is associated with an absolute decrease of 7% in mortality and a reduction of length of stay in the hospital of 5.85 days. This results in a reduction in costs of $14,555 in patients with sepsis without organ dysfunction, $17,134 in patients with sepsis with organ dysfunction, and $19,300 in patients with septic shock."
These findings are highly relevant to $ASEP's patented AI-driven sepsis diagnosis technology as their tests are confirmed within 1 hour and can be used to both treat and prevent Sepsis by detecting a unique gene expression profile highly associated with Sepsis and organ failure.
I'm looking forward to further updates from $ASEP - they clearly have a significant market opportunity and are set to benefit once their tests and products are taken to the market.
https://www.newswire.ca/news-releases/asep-medical-holdings-inc-announces-compelling-results-of-an-independent-sepsis-study-prepared-by-rti-health-solutions-810572620.html